



PRIOR AUTHORIZATION REQUEST

Celecoxib

Patient Information:

Name:	
Member ID:	
Address:	
City, State, Zip:	
Date of Birth:	

Prescriber Information:

Name:	
NPI:	
Phone Number:	
Fax Number:	
Address:	
City, State, Zip:	

Requested Medication

Rx Name:	
Rx Strength:	
Rx Quantity:	
Rx Frequency:	
Rx Route of Administration:	
Diagnosis and ICD Code:	

Your patient's prescription benefit requires that we review certain requests for coverage with the prescriber. You have prescribed a medication for your patient that requires Prior Authorization before benefit coverage or coverage of additional quantities can be provided. Please complete the following questions then fax this form to the toll-free number listed below. Upon receipt of the completed form, prescription benefit coverage will be determined based on the plan's rules.

SECTION A: Please note that supporting clinical documentation is required for ALL PA requests. Pharmacy prior authorization reviews can be subject to trial with additional medications that are not listed within the criteria. The policies are subject to change based on COMAR requirements, MDH transmittals and updates to treatment guidelines.

1	Does the patient have a history of non-steroidal anti-inflammatory (NSAID)-induced gastritis that was confirmed by esophagogastroduodenoscopy (EGD)? [If yes, skip to question 5.]	Yes	No
2	Is the patient at a high-risk for adverse gastrointestinal events: A) Age 65 years or older, B) History of gastrointestinal (GI) ulcer, GI bleeding or non-steroidal anti-inflammatory (NSAID)-induced gastritis, OR C) Currently taking corticosteroids (i.e., prednisone) or anticoagulants (i.e., warfarin, enoxaparin)? [If no, skip to question 4.]	Yes	No

If you have any
questions, call:
1-888-258-8250

Version 07.2025

PRIOR AUTHORIZATION REQUEST

- | | | | |
|---|--|-----|----|
| 3 | Is the patient taking a daily aspirin?
[If yes, no further questions.]
[If no, skip to question 5.] | Yes | No |
| 4 | Has the patient had inadequate pain relief with at least 3 formulary non-steroidal anti-inflammatory drugs (NSAIDs)?
[NOTE: Formulary NSAIDs include the following as prescription or over-the-counter (OTC): IBUPROFEN, NAPROXEN SODIUM, DICLOFENAC, ETODOLAC, KETOPROFEN, MELOXICAM, NABUMETONE, OXAPROZIN, PIROXICAM.]
[If no, no further questions.] | Yes | No |
| 5 | Does the patient have a diagnosis of juvenile rheumatoid arthritis (JRA) AND is at least 2 years of age?
[NOTE: Dosing for patients greater than 25 kg is 100 mg twice daily; patients 10-25 kg dosing is 50 mg twice daily.]
[If yes, no further questions.] | Yes | No |
| 6 | Did the patient have a recent (within the past 14 days) coronary artery bypass surgery (CABG)?
[If yes, no further questions.] | Yes | No |
| 7 | Is the patient greater than or equal to 18 years of age?
[If no, no further questions.] | Yes | No |
| 8 | Does the patient have a diagnosis of Osteoarthritis (OA)?
[NOTE: Please note the dose limit for OA is 200 mg/day.]
[If yes, no further questions.] | Yes | No |
| 9 | Does the patient have one of the following diagnoses: A) Rheumatoid arthritis (RA), B) Ankylosing spondylitis, C) Moderate to severe pain associated with orthopedic surgery, D) Psoriatic arthritis, E) Acute Pain, F) Primary dysmenorrhea?
[NOTE: Please note the dose limit is 400 mg/day.] | Yes | No |

Please document the diagnoses, symptoms, and/or any other information important to this review:

SECTION B: Physician Signature

PHYSICIAN SIGNATURE

DATE

FAX COMPLETED FORM TO: 1-833-896-0656

If you have any
questions, call:
1-888-258-8250

Version 07.2025



PRIOR AUTHORIZATION REQUEST

Disclaimer: An authorization is not a guarantee of payment. Member must be eligible at the time services are rendered. Services must be a covered Health Plan Benefit and medically necessary with prior authorization as per Plan policy and procedures.

Confidentiality: The information contained in this transmission is confidential and may be protected under the Health Insurance Portability and Accountability Act of 1996. If you are not the intended recipient any use, distribution, or copying is strictly prohibited. If you have received this facsimile in error, please notify us immediately and destroy this document.

If you have any
questions, call:
1-888-258-8250

Version 07.2025